| Literature DB >> 27399758 |
Jacques Robert1, James K Jancovich2.
Abstract
Ranaviruses (Iridoviridae) are large DNA viruses that are causing emerging infectious diseases at an alarming rate in both wild and captive cold blood vertebrate species all over the world. Although the general biology of these viruses that presents some similarities with poxvirus is characterized, many aspects of their replication cycles, host cell interactions and evolution still remain largely unclear, especially in vivo. Over several years, strategies to generate site-specific ranavirus recombinant, either expressing fluorescent reporter genes or deficient for particular viral genes, have been developed. We review here these strategies, the main ranavirus recombinants characterized and their usefulness for in vitro and in vivo studies.Entities:
Keywords: Amphibians; DNA viruses; Xenopus; iridovirus; reporter virus, recombinant virus
Mesh:
Year: 2016 PMID: 27399758 PMCID: PMC4974522 DOI: 10.3390/v8070187
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1(A) Schematic for generating ranavirus recombinant by site-specific integration of a selection cassette. This cassette consists of a fluorescent reporter gene fused to a drug resistance gene by a short linker that is under the control of a ranaviral or ectopic promoter. This cassette is flanked by a left and right sequence portion (500 bp) of the targeted site and is cloned into a convenient bacterial plasmid. Cells are transfected with the construct using lipofectin and then infected with wt ranavirus to generate homologous recombination. The selection is performed sequentially by virus replication in the presence the drug and then by isolation of fluorescent plaques. (B) Schematic representation of the standardized process to generate a recombination cassette for Ambystoma tigrinum virus (ATV). Primers are designed to amplify the neomycin resistance (GNR) cassette as well as approximately 1000 nt of the upstream (US) and downstream (DS) flanking sequences for each target open reading frame (ORF). Adapter sequence added to the 3′ end of the US sequence and the 5′ end of CMV promoter. In addition, a different adapter is added to the 3′ end of the cytomegalovirus promoter (CMV-GNR) cassette and the 5′ end of the DS sequence. A standardized overlapping PCR protocol assembles the recombination cassette that is then agarose gel purified and re-amplified using primers that truncate the US and DS sequences t. This PCR product is then used to generate a recombinant virus.
Figure 2Detection of FV3-GFP knock-in mutant expressing GFP reporter under the control of the immediate early 18K promoter during infection in vitro in mammalian cell lines and in vivo in X. laevis tadpoles. (A) BHK cells at 2 h post-infection at permissive (30 °C) temperature; (B) mouse BV2 macrophage-like microglial cells at 24 h post-infection at permissive (30 °C) temperature; (C) mouse sertoli macrophage TM4 at 24 h post-infection at non-permissive (37 °C) temperature; and (D,E) midbrain view of pre-metamorphic tadpole brain at 1 day post-infection at low (D) and higher (E) magnification. (*) Indicates the same melanophore in panel D and E. Images are composite of phase contrast and fluorescence for cells (A–C) and of bright field and fluorescence of the whole-mounted tadpole, taken under a Leica DMIRB inverted fluorescence microscope and Infinity 2 digital camera (objectives ×5/×10/×20; Zeiss). Digital images were analyzed and processed by ImageJ software.
Recombinant Ranaviruses.
| Virus | ORF | Predicted Function | Mutant Phenotype | Reporter Marker | Reference |
|---|---|---|---|---|---|
| FV3 | |||||
| 26R | eIF2α homologue | antagonist of PKR; IFNs; increased apoptosis; reduced pathogenesis | EGFP-puromycin resistance | [ | |
| 82R | ICP-18 | increased apoptosis; increased induction of type I IFN; reduced pathogenesis | EGFP-puromycin resistance | “ | |
| 52L | β-hydroxysteroid dehydrogenase homolog | tbd; reduced pathogenesis | EGFP-puromycin resistance | [ | |
| 64R | caspase activation & recruitment domain-containing (CARD) protein | IFNs; increased apoptosis; reduced pathogenesis | EGFP-puromycin resistance | “ | |
| ATV | |||||
| 57R | eIF2α homologue | antagonist of PKZ; reduced pathogenesis | neomycin resistance | [ | |
| 11R | unknown | essential gene | GFP-neomycin resistance | [ | |
| 25R | RNase III | degrades RNA | GFP-neomycin resistance | “ | |
| 40L | CARD-containing gene | tbd; see FV3 above | GFP-neomycin resistance | “ | |
| 53R | Unknown—essential | essential gene | GFP-neomycin resistance | “ | |
| 54R | unknown | tbd | GFP-neomycin resistance | “ | |
| RGV | |||||
| 53R | viral envelope protein | green virus | EGFP | [ | |
| 92R | thymidine kinase (TK) | non-essential | EGFP | “ | |
| 53R | viral envelope protein | required for viral production; reduced growth when not expressed | IPTG inducible; EGFP | [ | |
| 2L | viral envelope protein | required for viral production; reduced growth when not expressed | IPTG inducible; EGFP | [ | |
| 92R67R | TK and deoxyuridine triphosphatase (dUTPase, DUT) | EGFP/RFP | [ | ||
| ESV | |||||
| 114L | dihydrofolate reductase (DHFR) | non-essential | EGFP-neomycin resistance | [ | |
| STIV | |||||
| VP55 | viral envelope protein | green virus | EGFP-VP55 fusion | [ |
tbd = to be determined; IFNs = interferon sensitivity; “ =same reference as above.